Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema Article Swipe

View

Susan B. Bressler , Abhijit Barve , Prasanna C. Ganapathi , Katrin Beckmann , Rajendra S. Apte , Dennis M. Marcus , Kristīne Baumane , Somesh Agarwal , Piotr Oleksy , David A. Reichstein , Sunil S. Patel , Jan Ernest , Rózsa Dégı̀ , Vishali Gupta , Genichiro Kishino , Motohiro Kamei , Subramanian Loganathan , Nauman Chaudhry , David A. Reichstein , Ali Tabassian , Howard F. Fine , Raymond N. Sjaarda , Dennis M. Marcus , Mark Barakat , Pravin U. Dugel , David Eichenbaum , Amr Dessouki , Adam Berger , BRYAN N. ANGLE , Margaret Chang , Sunil Patel , David M. Brown , Allen B. Thach , Carl W. Baker , Alan J Gordon , Sam E. Mansour , Gregory M Fox , D. Virgil Alfaro , John B. Davies , Ghassan R Ghorayeb , Glenn Stoller , Thomas Mark Johnson , Jan Němčanský , J Řehák , Jan Studnička , Jan Ernest , Vladimír Korda , Miroslav Veith , Daniel Krzyzanek , B Kalvodová , Pavel Stodůlka , Nicolas Feltgen , Katrin Lorenz PD , Salvatore Grisanti , Maria Andreea Gamulescu , Ulrich Kellner , Walter Sekundo , Claudia Dahlke , Oliver Zeitz , Kristīne Baumane , Guna Laganovska , Signe Ozolina , Attila Vajas , András Seres , Alexis Tsorbatzoglou , Judit Radnoti , Katalin Kiss , Katalin Gombos , Rózsa Dégı̀ , Balázs Varsányi , Ágnes Kerényi , Sumiyo Noge , Tomoyuki Muramatsu , T. Kaga , Hideyasu Oh , Miki Watanabe , Yuji Oshima , Hideaki Fujita , Genichiro Kishino , Tsukasa Hanemoto , Kōji Murata , Takashi Kitaoka , Isao Saito , Teruyo Tanabe , Nobuyuki Ebihara , Hiroko Imaizumi , Kiyoshi Ishii , Motohiro Kamei , Minoru Furuta , Akira Ojima , Osamu Sawada , Tsutomu Kawasaki , Hiroshi Otake , Norihito Doi , Keitetsu Abe , Satoshi Matsuda , Namie Kobayashi , Yuki Yoshizumi , M V Budzinskaya , O.I. Lebedev ·

YOU? · · 2024 · Open Access · · DOI: https://doi.org/10.1001/jamaophthalmol.2024.3458

Importance Biosimilars may be lower-cost alternatives to originator biologic products, potentially offering expanded access or reduced economic burden, but have not been evaluated with aflibercept in diabetic macular edema (DME). Objective To compare efficacy and safety of MYL-1701P, an aflibercept biosimilar, with reference aflibercept (Eylea [Regeneron]) in DME. Design, Setting, and Participants This was a double-masked, randomized clinical trial that included participants at 77 centers across the US, Europe, Japan, and India. Included in the analysis were individuals 18 years and older with type 1 or type 2 diabetes with central DME and best-corrected visual acuity (BCVA) letter score of 73 to 38 in the study eye using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Study data were analyzed from October to December 2021. Interventions Formulations of MYL-1701P (0.5-mg vial) or reference aflibercept every 4 weeks for 5 consecutive intravitreal injections, followed by every 8 weeks through week 52. Main Outcomes and Measures The primary outcome was the adjusted difference in least squares mean (SE) change from baseline BCVA letter score at week 8 with an equivalence margin of −3 to +3 letters. Secondary outcomes included change in central subfield thickness (CST), BCVA, number of injections over 52 weeks, incidence of adverse events (AEs), and antidrug antibodies (ADAs). Results A total of 355 participants (mean [SD] age, 62.2 [9.2] years; 216 male [60.8%]) were randomized to MYL-1701P (179 participants [50.4%]) and aflibercept (176 participants [49.6%]). At week 8, mean (SE) change in BCVA was 6.60 (0.55) letters vs 6.56 (0.55) letters in the MYL-1701P vs aflibercept groups. The adjusted mean difference of 0.04 letters (90% CI, −1.16 to 1.24 letters) met the primary outcome. At week 8, mean (SE) change in CST was −112 (7) μm vs −124 (7) μm in the MYL-1701P vs aflibercept groups (adjusted mean difference, 12 μm; 90% CI, −3 to 26 μm). The incidence of treatment-emergent AEs in the MYL-1701P and aflibercept arms were ocular (30.9% [55 of 178] vs 29.5% [52 of 176]), serious ocular (0.6% [1 of 178] vs 1.1% [2 of 176]), nonocular (65.2% [116 of 178] vs 65.3% [115 of 176]), and serious nonocular (16.9% [30 of 178] vs 11.9% [21 of 176]). The mean (SD) total number of injections was 8.4 (2.1) vs 8.7 (1.8) in the MYL-1701P vs aflibercept groups. The incidence of treatment-induced or treatment-boosted ADAs was 2.8% (5 of 177) vs 5.7% (10 of 176) in the MYL-1701P vs aflibercept arms. Conclusions and Relevance MYL-1701P demonstrated clinical equivalence in regard to efficacy, with comparable safety and immunogenicity, to reference aflibercept. These findings support use of MLY-1701P as an alternative to reference aflibercept. Trial Registration ClinicalTrials.gov Identifier: NCT03610646

Related Topics

Medicine

Diabetic Retinopathy

Randomized Controlled Trial

Concepts

Aflibercept Medicine Visual acuity Macular edema Diabetic retinopathy Adverse effect Randomized controlled trial Ophthalmology Ranibizumab Diabetes mellitus Incidence (geometry) Internal medicine Bevacizumab Optics Endocrinology Physics Chemotherapy

Metadata

Type: article
Language: en
Landing Page: https://doi.org/10.1001/jamaophthalmol.2024.3458
OA Status: green
Cited By: 7
References: 10
Related Works: 10
OpenAlex ID: https://openalex.org/W4402482350

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4402482350

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1001/jamaophthalmol.2024.3458

Digital Object Identifier
Title: Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema

Work title
Type: article

OpenAlex work type
Language: en

Primary language
Publication year: 2024

Year of publication
Publication date: 2024-09-12

Full publication date if available
Authors: Susan B. Bressler, Abhijit Barve, Prasanna C. Ganapathi, Katrin Beckmann, Rajendra S. Apte, Dennis M. Marcus, Kristīne Baumane, Somesh Agarwal, Piotr Oleksy, David A. Reichstein, Sunil S. Patel, Jan Ernest, Rózsa Dégı̀, Vishali Gupta, Genichiro Kishino, Motohiro Kamei, Subramanian Loganathan, Nauman Chaudhry, David A. Reichstein, Ali Tabassian, Howard F. Fine, Raymond N. Sjaarda, Dennis M. Marcus, Mark Barakat, Pravin U. Dugel, David Eichenbaum, Amr Dessouki, Adam Berger, BRYAN N. ANGLE, Margaret Chang, Sunil Patel, David M. Brown, Allen B. Thach, Carl W. Baker, Alan J Gordon, Sam E. Mansour, Gregory M Fox, D. Virgil Alfaro, John B. Davies, Ghassan R Ghorayeb, Glenn Stoller, Thomas Mark Johnson, Jan Němčanský, J Řehák, Jan Studnička, Jan Ernest, Vladimír Korda, Miroslav Veith, Daniel Krzyzanek, B Kalvodová, Pavel Stodůlka, Nicolas Feltgen, Katrin Lorenz PD, Salvatore Grisanti, Maria Andreea Gamulescu, Ulrich Kellner, Walter Sekundo, Claudia Dahlke, Oliver Zeitz, Kristīne Baumane, Guna Laganovska, Signe Ozolina, Attila Vajas, András Seres, Alexis Tsorbatzoglou, Judit Radnoti, Katalin Kiss, Katalin Gombos, Rózsa Dégı̀, Balázs Varsányi, Ágnes Kerényi, Sumiyo Noge, Tomoyuki Muramatsu, T. Kaga, Hideyasu Oh, Miki Watanabe, Yuji Oshima, Hideaki Fujita, Genichiro Kishino, Tsukasa Hanemoto, Kōji Murata, Takashi Kitaoka, Isao Saito, Teruyo Tanabe, Nobuyuki Ebihara, Hiroko Imaizumi, Kiyoshi Ishii, Motohiro Kamei, Minoru Furuta, Akira Ojima, Osamu Sawada, Tsutomu Kawasaki, Hiroshi Otake, Norihito Doi, Keitetsu Abe, Satoshi Matsuda, Namie Kobayashi, Yuki Yoshizumi, M V Budzinskaya, O.I. Lebedev

List of authors in order
Landing page: https://doi.org/10.1001/jamaophthalmol.2024.3458

Publisher landing page
Open access: Yes

Whether a free full text is available
OA status: green

Open access status per OpenAlex
Concepts: Aflibercept, Medicine, Visual acuity, Macular edema, Diabetic retinopathy, Adverse effect, Randomized controlled trial, Ophthalmology, Ranibizumab, Diabetes mellitus, Incidence (geometry), Internal medicine, Bevacizumab, Optics, Endocrinology, Physics, Chemotherapy

Top concepts (fields/topics) attached by OpenAlex
Cited by: 7

Total citation count in OpenAlex
Citations by year (recent): 2025: 7

Per-year citation counts (last 5 years)
References (count): 10

Number of works referenced by this work
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4402482350
doi	https://doi.org/10.1001/jamaophthalmol.2024.3458
ids.doi	https://doi.org/10.1001/jamaophthalmol.2024.3458
ids.pmid	https://pubmed.ncbi.nlm.nih.gov/39264599
ids.openalex	https://openalex.org/W4402482350
fwci	8.36350468
mesh[0].qualifier_ui
mesh[0].descriptor_ui	D006801
mesh[0].is_major_topic	False
mesh[0].qualifier_name
mesh[0].descriptor_name	Humans
mesh[1].qualifier_ui	Q000627
mesh[1].descriptor_ui	D011993
mesh[1].is_major_topic	True
mesh[1].qualifier_name	therapeutic use
mesh[1].descriptor_name	Recombinant Fusion Proteins
mesh[2].qualifier_ui	Q000008
mesh[2].descriptor_ui	D011993
mesh[2].is_major_topic	True
mesh[2].qualifier_name	administration & dosage
mesh[2].descriptor_name	Recombinant Fusion Proteins
mesh[3].qualifier_ui	Q000008
mesh[3].descriptor_ui	D040262
mesh[3].is_major_topic	True
mesh[3].qualifier_name	administration & dosage
mesh[3].descriptor_name	Receptors, Vascular Endothelial Growth Factor
mesh[4].qualifier_ui	Q000188
mesh[4].descriptor_ui	D003930
mesh[4].is_major_topic	True
mesh[4].qualifier_name	drug therapy
mesh[4].descriptor_name	Diabetic Retinopathy
mesh[5].qualifier_ui	Q000175
mesh[5].descriptor_ui	D003930
mesh[5].is_major_topic	True
mesh[5].qualifier_name	diagnosis
mesh[5].descriptor_name	Diabetic Retinopathy
mesh[6].qualifier_ui	Q000503
mesh[6].descriptor_ui	D003930
mesh[6].is_major_topic	True
mesh[6].qualifier_name	physiopathology
mesh[6].descriptor_name	Diabetic Retinopathy
mesh[7].qualifier_ui	Q000188
mesh[7].descriptor_ui	D008269
mesh[7].is_major_topic	True
mesh[7].qualifier_name	drug therapy
mesh[7].descriptor_name	Macular Edema
mesh[8].qualifier_ui	Q000503
mesh[8].descriptor_ui	D008269
mesh[8].is_major_topic	True
mesh[8].qualifier_name	physiopathology
mesh[8].descriptor_name	Macular Edema
mesh[9].qualifier_ui	Q000175
mesh[9].descriptor_ui	D008269
mesh[9].is_major_topic	True
mesh[9].qualifier_name	diagnosis
mesh[9].descriptor_name	Macular Edema
mesh[10].qualifier_ui
mesh[10].descriptor_ui	D008297
mesh[10].is_major_topic	False
mesh[10].qualifier_name
mesh[10].descriptor_name	Male
mesh[11].qualifier_ui
mesh[11].descriptor_ui	D004311
mesh[11].is_major_topic	False
mesh[11].qualifier_name
mesh[11].descriptor_name	Double-Blind Method
mesh[12].qualifier_ui
mesh[12].descriptor_ui	D005260
mesh[12].is_major_topic	False
mesh[12].qualifier_name
mesh[12].descriptor_name	Female
mesh[13].qualifier_ui
mesh[13].descriptor_ui	D058449
mesh[13].is_major_topic	True
mesh[13].qualifier_name
mesh[13].descriptor_name	Intravitreal Injections
mesh[14].qualifier_ui	Q000502
mesh[14].descriptor_ui	D014792
mesh[14].is_major_topic	True
mesh[14].qualifier_name	physiology
mesh[14].descriptor_name	Visual Acuity
mesh[15].qualifier_ui
mesh[15].descriptor_ui	D008875
mesh[15].is_major_topic	False
mesh[15].qualifier_name
mesh[15].descriptor_name	Middle Aged
mesh[16].qualifier_ui	Q000008
mesh[16].descriptor_ui	D020533
mesh[16].is_major_topic	True
mesh[16].qualifier_name	administration & dosage
mesh[16].descriptor_name	Angiogenesis Inhibitors
mesh[17].qualifier_ui	Q000627
mesh[17].descriptor_ui	D020533
mesh[17].is_major_topic	True
mesh[17].qualifier_name	therapeutic use
mesh[17].descriptor_name	Angiogenesis Inhibitors
mesh[18].qualifier_ui	Q000009
mesh[18].descriptor_ui	D020533
mesh[18].is_major_topic	True
mesh[18].qualifier_name	adverse effects
mesh[18].descriptor_name	Angiogenesis Inhibitors
mesh[19].qualifier_ui	Q000627
mesh[19].descriptor_ui	D059451
mesh[19].is_major_topic	True
mesh[19].qualifier_name	therapeutic use
mesh[19].descriptor_name	Biosimilar Pharmaceuticals
mesh[20].qualifier_ui	Q000009
mesh[20].descriptor_ui	D059451
mesh[20].is_major_topic	True
mesh[20].qualifier_name	adverse effects
mesh[20].descriptor_name	Biosimilar Pharmaceuticals
mesh[21].qualifier_ui
mesh[21].descriptor_ui	D016896
mesh[21].is_major_topic	False
mesh[21].qualifier_name
mesh[21].descriptor_name	Treatment Outcome
mesh[22].qualifier_ui
mesh[22].descriptor_ui	D000368
mesh[22].is_major_topic	False
mesh[22].qualifier_name
mesh[22].descriptor_name	Aged
mesh[23].qualifier_ui	Q000037
mesh[23].descriptor_ui	D042461
mesh[23].is_major_topic	False
mesh[23].qualifier_name	antagonists & inhibitors
mesh[23].descriptor_name	Vascular Endothelial Growth Factor A
mesh[24].qualifier_ui
mesh[24].descriptor_ui	D041623
mesh[24].is_major_topic	False
mesh[24].qualifier_name
mesh[24].descriptor_name	Tomography, Optical Coherence
mesh[25].qualifier_ui
mesh[25].descriptor_ui	D006801
mesh[25].is_major_topic	False
mesh[25].qualifier_name
mesh[25].descriptor_name	Humans
mesh[26].qualifier_ui	Q000627
mesh[26].descriptor_ui	D011993
mesh[26].is_major_topic	True
mesh[26].qualifier_name	therapeutic use
mesh[26].descriptor_name	Recombinant Fusion Proteins
mesh[27].qualifier_ui	Q000008
mesh[27].descriptor_ui	D011993
mesh[27].is_major_topic	True
mesh[27].qualifier_name	administration & dosage
mesh[27].descriptor_name	Recombinant Fusion Proteins
mesh[28].qualifier_ui	Q000008
mesh[28].descriptor_ui	D040262
mesh[28].is_major_topic	True
mesh[28].qualifier_name	administration & dosage
mesh[28].descriptor_name	Receptors, Vascular Endothelial Growth Factor
mesh[29].qualifier_ui	Q000188
mesh[29].descriptor_ui	D003930
mesh[29].is_major_topic	True
mesh[29].qualifier_name	drug therapy
mesh[29].descriptor_name	Diabetic Retinopathy
mesh[30].qualifier_ui	Q000175
mesh[30].descriptor_ui	D003930
mesh[30].is_major_topic	True
mesh[30].qualifier_name	diagnosis
mesh[30].descriptor_name	Diabetic Retinopathy
mesh[31].qualifier_ui	Q000503
mesh[31].descriptor_ui	D003930
mesh[31].is_major_topic	True
mesh[31].qualifier_name	physiopathology
mesh[31].descriptor_name	Diabetic Retinopathy
mesh[32].qualifier_ui	Q000188
mesh[32].descriptor_ui	D008269
mesh[32].is_major_topic	True
mesh[32].qualifier_name	drug therapy
mesh[32].descriptor_name	Macular Edema
mesh[33].qualifier_ui	Q000503
mesh[33].descriptor_ui	D008269
mesh[33].is_major_topic	True
mesh[33].qualifier_name	physiopathology
mesh[33].descriptor_name	Macular Edema
mesh[34].qualifier_ui	Q000175
mesh[34].descriptor_ui	D008269
mesh[34].is_major_topic	True
mesh[34].qualifier_name	diagnosis
mesh[34].descriptor_name	Macular Edema
mesh[35].qualifier_ui
mesh[35].descriptor_ui	D008297
mesh[35].is_major_topic	False
mesh[35].qualifier_name
mesh[35].descriptor_name	Male
mesh[36].qualifier_ui
mesh[36].descriptor_ui	D004311
mesh[36].is_major_topic	False
mesh[36].qualifier_name
mesh[36].descriptor_name	Double-Blind Method
mesh[37].qualifier_ui
mesh[37].descriptor_ui	D005260
mesh[37].is_major_topic	False
mesh[37].qualifier_name
mesh[37].descriptor_name	Female
mesh[38].qualifier_ui
mesh[38].descriptor_ui	D058449
mesh[38].is_major_topic	True
mesh[38].qualifier_name
mesh[38].descriptor_name	Intravitreal Injections
mesh[39].qualifier_ui	Q000502
mesh[39].descriptor_ui	D014792
mesh[39].is_major_topic	True
mesh[39].qualifier_name	physiology
mesh[39].descriptor_name	Visual Acuity
mesh[40].qualifier_ui
mesh[40].descriptor_ui	D008875
mesh[40].is_major_topic	False
mesh[40].qualifier_name
mesh[40].descriptor_name	Middle Aged
mesh[41].qualifier_ui	Q000008
mesh[41].descriptor_ui	D020533
mesh[41].is_major_topic	True
mesh[41].qualifier_name	administration & dosage
mesh[41].descriptor_name	Angiogenesis Inhibitors
mesh[42].qualifier_ui	Q000627
mesh[42].descriptor_ui	D020533
mesh[42].is_major_topic	True
mesh[42].qualifier_name	therapeutic use
mesh[42].descriptor_name	Angiogenesis Inhibitors
mesh[43].qualifier_ui	Q000009
mesh[43].descriptor_ui	D020533
mesh[43].is_major_topic	True
mesh[43].qualifier_name	adverse effects
mesh[43].descriptor_name	Angiogenesis Inhibitors
mesh[44].qualifier_ui	Q000627
mesh[44].descriptor_ui	D059451
mesh[44].is_major_topic	True
mesh[44].qualifier_name	therapeutic use
mesh[44].descriptor_name	Biosimilar Pharmaceuticals
mesh[45].qualifier_ui	Q000009
mesh[45].descriptor_ui	D059451
mesh[45].is_major_topic	True
mesh[45].qualifier_name	adverse effects
mesh[45].descriptor_name	Biosimilar Pharmaceuticals
mesh[46].qualifier_ui
mesh[46].descriptor_ui	D016896
mesh[46].is_major_topic	False
mesh[46].qualifier_name
mesh[46].descriptor_name	Treatment Outcome
mesh[47].qualifier_ui
mesh[47].descriptor_ui	D000368
mesh[47].is_major_topic	False
mesh[47].qualifier_name
mesh[47].descriptor_name	Aged
mesh[48].qualifier_ui	Q000037
mesh[48].descriptor_ui	D042461
mesh[48].is_major_topic	False
mesh[48].qualifier_name	antagonists & inhibitors
mesh[48].descriptor_name	Vascular Endothelial Growth Factor A
mesh[49].qualifier_ui
mesh[49].descriptor_ui	D041623
mesh[49].is_major_topic	False
mesh[49].qualifier_name
mesh[49].descriptor_name	Tomography, Optical Coherence
type	article
title	Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema
biblio.issue	10
biblio.volume	142
biblio.last_page	952
biblio.first_page	952
topics[0].id	https://openalex.org/T10170
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	0.9965999722480774
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2731
topics[0].subfield.display_name	Ophthalmology
topics[0].display_name	Retinal Diseases and Treatments
topics[1].id	https://openalex.org/T12255
topics[1].field.id	https://openalex.org/fields/24
topics[1].field.display_name	Immunology and Microbiology
topics[1].score	0.9950000047683716
topics[1].domain.id	https://openalex.org/domains/1
topics[1].domain.display_name	Life Sciences
topics[1].subfield.id	https://openalex.org/subfields/2403
topics[1].subfield.display_name	Immunology
topics[1].display_name	Biosimilars and Bioanalytical Methods
topics[2].id	https://openalex.org/T10993
topics[2].field.id	https://openalex.org/fields/24
topics[2].field.display_name	Immunology and Microbiology
topics[2].score	0.9922999739646912
topics[2].domain.id	https://openalex.org/domains/1
topics[2].domain.display_name	Life Sciences
topics[2].subfield.id	https://openalex.org/subfields/2403
topics[2].subfield.display_name	Immunology
topics[2].display_name	Complement system in diseases
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C2778749236
concepts[0].level	4
concepts[0].score	0.9720736742019653
concepts[0].wikidata	https://www.wikidata.org/wiki/Q4689286
concepts[0].display_name	Aflibercept
concepts[1].id	https://openalex.org/C71924100
concepts[1].level	0
concepts[1].score	0.9579583406448364
concepts[1].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[1].display_name	Medicine
concepts[2].id	https://openalex.org/C2778257484
concepts[2].level	2
concepts[2].score	0.6052001118659973
concepts[2].wikidata	https://www.wikidata.org/wiki/Q555066
concepts[2].display_name	Visual acuity
concepts[3].id	https://openalex.org/C2780347916
concepts[3].level	3
concepts[3].score	0.5985487103462219
concepts[3].wikidata	https://www.wikidata.org/wiki/Q1813737
concepts[3].display_name	Macular edema
concepts[4].id	https://openalex.org/C2779829184
concepts[4].level	3
concepts[4].score	0.5699589848518372
concepts[4].wikidata	https://www.wikidata.org/wiki/Q631361
concepts[4].display_name	Diabetic retinopathy
concepts[5].id	https://openalex.org/C197934379
concepts[5].level	2
concepts[5].score	0.543950080871582
concepts[5].wikidata	https://www.wikidata.org/wiki/Q2047938
concepts[5].display_name	Adverse effect
concepts[6].id	https://openalex.org/C168563851
concepts[6].level	2
concepts[6].score	0.49736884236335754
concepts[6].wikidata	https://www.wikidata.org/wiki/Q1436668
concepts[6].display_name	Randomized controlled trial
concepts[7].id	https://openalex.org/C118487528
concepts[7].level	1
concepts[7].score	0.49615034461021423
concepts[7].wikidata	https://www.wikidata.org/wiki/Q161437
concepts[7].display_name	Ophthalmology
concepts[8].id	https://openalex.org/C2781100027
concepts[8].level	4
concepts[8].score	0.42909783124923706
concepts[8].wikidata	https://www.wikidata.org/wiki/Q414270
concepts[8].display_name	Ranibizumab
concepts[9].id	https://openalex.org/C555293320
concepts[9].level	2
concepts[9].score	0.4253891408443451
concepts[9].wikidata	https://www.wikidata.org/wiki/Q12206
concepts[9].display_name	Diabetes mellitus
concepts[10].id	https://openalex.org/C61511704
concepts[10].level	2
concepts[10].score	0.41417649388313293
concepts[10].wikidata	https://www.wikidata.org/wiki/Q1671857
concepts[10].display_name	Incidence (geometry)
concepts[11].id	https://openalex.org/C126322002
concepts[11].level	1
concepts[11].score	0.32486552000045776
concepts[11].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[11].display_name	Internal medicine
concepts[12].id	https://openalex.org/C2777802072
concepts[12].level	3
concepts[12].score	0.2931811213493347
concepts[12].wikidata	https://www.wikidata.org/wiki/Q413299
concepts[12].display_name	Bevacizumab
concepts[13].id	https://openalex.org/C120665830
concepts[13].level	1
concepts[13].score	0.0
concepts[13].wikidata	https://www.wikidata.org/wiki/Q14620
concepts[13].display_name	Optics
concepts[14].id	https://openalex.org/C134018914
concepts[14].level	1
concepts[14].score	0.0
concepts[14].wikidata	https://www.wikidata.org/wiki/Q162606
concepts[14].display_name	Endocrinology
concepts[15].id	https://openalex.org/C121332964
concepts[15].level	0
concepts[15].score	0.0
concepts[15].wikidata	https://www.wikidata.org/wiki/Q413
concepts[15].display_name	Physics
concepts[16].id	https://openalex.org/C2776694085
concepts[16].level	2
concepts[16].score	0.0
concepts[16].wikidata	https://www.wikidata.org/wiki/Q974135
concepts[16].display_name	Chemotherapy
keywords[0].id	https://openalex.org/keywords/aflibercept
keywords[0].score	0.9720736742019653
keywords[0].display_name	Aflibercept
keywords[1].id	https://openalex.org/keywords/medicine
keywords[1].score	0.9579583406448364
keywords[1].display_name	Medicine
keywords[2].id	https://openalex.org/keywords/visual-acuity
keywords[2].score	0.6052001118659973
keywords[2].display_name	Visual acuity
keywords[3].id	https://openalex.org/keywords/macular-edema
keywords[3].score	0.5985487103462219
keywords[3].display_name	Macular edema
keywords[4].id	https://openalex.org/keywords/diabetic-retinopathy
keywords[4].score	0.5699589848518372
keywords[4].display_name	Diabetic retinopathy
keywords[5].id	https://openalex.org/keywords/adverse-effect
keywords[5].score	0.543950080871582
keywords[5].display_name	Adverse effect
keywords[6].id	https://openalex.org/keywords/randomized-controlled-trial
keywords[6].score	0.49736884236335754
keywords[6].display_name	Randomized controlled trial
keywords[7].id	https://openalex.org/keywords/ophthalmology
keywords[7].score	0.49615034461021423
keywords[7].display_name	Ophthalmology
keywords[8].id	https://openalex.org/keywords/ranibizumab
keywords[8].score	0.42909783124923706
keywords[8].display_name	Ranibizumab
keywords[9].id	https://openalex.org/keywords/diabetes-mellitus
keywords[9].score	0.4253891408443451
keywords[9].display_name	Diabetes mellitus
keywords[10].id	https://openalex.org/keywords/incidence
keywords[10].score	0.41417649388313293
keywords[10].display_name	Incidence (geometry)
keywords[11].id	https://openalex.org/keywords/internal-medicine
keywords[11].score	0.32486552000045776
keywords[11].display_name	Internal medicine
keywords[12].id	https://openalex.org/keywords/bevacizumab
keywords[12].score	0.2931811213493347
keywords[12].display_name	Bevacizumab
language	en
locations[0].id	doi:10.1001/jamaophthalmol.2024.3458
locations[0].is_oa	False
locations[0].source.id	https://openalex.org/S68724622
locations[0].source.issn	2168-6165, 2168-6173
locations[0].source.type	journal
locations[0].source.is_oa	False
locations[0].source.issn_l	2168-6165
locations[0].source.is_core	True
locations[0].source.is_in_doaj	False
locations[0].source.display_name	JAMA Ophthalmology
locations[0].source.host_organization	https://openalex.org/P4310320259
locations[0].source.host_organization_name	American Medical Association
locations[0].source.host_organization_lineage	https://openalex.org/P4310320259
locations[0].license
locations[0].pdf_url
locations[0].version	publishedVersion
locations[0].raw_type	journal-article
locations[0].license_id
locations[0].is_accepted	True
locations[0].is_published	True
locations[0].raw_source_name	JAMA Ophthalmology
locations[0].landing_page_url	https://doi.org/10.1001/jamaophthalmol.2024.3458
locations[1].id	pmid:39264599
locations[1].is_oa	False
locations[1].source.id	https://openalex.org/S4306525036
locations[1].source.issn
locations[1].source.type	repository
locations[1].source.is_oa	False
locations[1].source.issn_l
locations[1].source.is_core	False
locations[1].source.is_in_doaj	False
locations[1].source.display_name	PubMed
locations[1].source.host_organization	https://openalex.org/I1299303238
locations[1].source.host_organization_name	National Institutes of Health
locations[1].source.host_organization_lineage	https://openalex.org/I1299303238
locations[1].license
locations[1].pdf_url
locations[1].version	publishedVersion
locations[1].raw_type
locations[1].license_id
locations[1].is_accepted	True
locations[1].is_published	True
locations[1].raw_source_name	JAMA ophthalmology
locations[1].landing_page_url	https://pubmed.ncbi.nlm.nih.gov/39264599
locations[2].id	pmh:oai:publicatio.bibl.u-szeged.hu:36897
locations[2].is_oa	True
locations[2].source.id	https://openalex.org/S4306400436
locations[2].source.issn
locations[2].source.type	repository
locations[2].source.is_oa	False
locations[2].source.issn_l
locations[2].source.is_core	False
locations[2].source.is_in_doaj	False
locations[2].source.display_name	SZTE Publicatio Repozitórium (University of Szeged)
locations[2].source.host_organization	https://openalex.org/I227486990
locations[2].source.host_organization_name	University of Szeged
locations[2].source.host_organization_lineage	https://openalex.org/I227486990
locations[2].license	other-oa
locations[2].pdf_url
locations[2].version	acceptedVersion
locations[2].raw_type	PeerReviewed
locations[2].license_id	https://openalex.org/licenses/other-oa
locations[2].is_accepted	True
locations[2].is_published	False
locations[2].raw_source_name
locations[2].landing_page_url
locations[3].id	pmh:oai:pubmedcentral.nih.gov:11393752
locations[3].is_oa	True
locations[3].source.id	https://openalex.org/S2764455111
locations[3].source.issn
locations[3].source.type	repository
locations[3].source.is_oa	False
locations[3].source.issn_l
locations[3].source.is_core	False
locations[3].source.is_in_doaj	False
locations[3].source.display_name	PubMed Central
locations[3].source.host_organization	https://openalex.org/I1299303238
locations[3].source.host_organization_name	National Institutes of Health
locations[3].source.host_organization_lineage	https://openalex.org/I1299303238
locations[3].license	other-oa
locations[3].pdf_url
locations[3].version	submittedVersion
locations[3].raw_type	Text
locations[3].license_id	https://openalex.org/licenses/other-oa
locations[3].is_accepted	False
locations[3].is_published	False
locations[3].raw_source_name	JAMA Ophthalmol
locations[3].landing_page_url	https://www.ncbi.nlm.nih.gov/pmc/articles/11393752
indexed_in	crossref, pubmed
authorships[0].author.id	https://openalex.org/A5112773093
authorships[0].author.orcid
authorships[0].author.display_name	Susan B. Bressler
authorships[0].countries	US
authorships[0].affiliations[0].institution_ids	https://openalex.org/I145311948, https://openalex.org/I2799853436
authorships[0].affiliations[0].raw_affiliation_string	Wilmer Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
authorships[0].institutions[0].id	https://openalex.org/I2799853436
authorships[0].institutions[0].ror	https://ror.org/037zgn354
authorships[0].institutions[0].type	healthcare
authorships[0].institutions[0].lineage	https://openalex.org/I2799853436
authorships[0].institutions[0].country_code	US
authorships[0].institutions[0].display_name	Johns Hopkins Medicine
authorships[0].institutions[1].id	https://openalex.org/I145311948
authorships[0].institutions[1].ror	https://ror.org/00za53h95
authorships[0].institutions[1].type	education
authorships[0].institutions[1].lineage	https://openalex.org/I145311948
authorships[0].institutions[1].country_code	US
authorships[0].institutions[1].display_name	Johns Hopkins University
authorships[0].author_position	first
authorships[0].raw_author_name	Susan B. Bressler
authorships[0].is_corresponding	False
authorships[0].raw_affiliation_strings	Wilmer Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
authorships[1].author.id	https://openalex.org/A5020953670
authorships[1].author.orcid	https://orcid.org/0000-0002-2070-3147
authorships[1].author.display_name	Abhijit Barve
authorships[1].affiliations[0].raw_affiliation_string	Viatris Inc, Canonsburg, Pennsylvania
authorships[1].author_position	middle
authorships[1].raw_author_name	Abhijit Barve
authorships[1].is_corresponding	False
authorships[1].raw_affiliation_strings	Viatris Inc, Canonsburg, Pennsylvania
authorships[2].author.id	https://openalex.org/A5107159930
authorships[2].author.orcid
authorships[2].author.display_name	Prasanna C. Ganapathi
authorships[2].affiliations[0].raw_affiliation_string	Viatris, Bangalore, India
authorships[2].author_position	middle
authorships[2].raw_author_name	Prasanna C. Ganapathi
authorships[2].is_corresponding	False
authorships[2].raw_affiliation_strings	Viatris, Bangalore, India
authorships[3].author.id	https://openalex.org/A5019605846
authorships[3].author.orcid
authorships[3].author.display_name	Katrin Beckmann
authorships[3].affiliations[0].raw_affiliation_string	Viatris Healthcare GmbH, Hannover, Germany
authorships[3].author_position	middle
authorships[3].raw_author_name	Katrin Beckmann
authorships[3].is_corresponding	False
authorships[3].raw_affiliation_strings	Viatris Healthcare GmbH, Hannover, Germany
authorships[4].author.id	https://openalex.org/A5085265068
authorships[4].author.orcid	https://orcid.org/0000-0003-2281-2336
authorships[4].author.display_name	Rajendra S. Apte
authorships[4].countries	US
authorships[4].affiliations[0].institution_ids	https://openalex.org/I204465549
authorships[4].affiliations[0].raw_affiliation_string	Washington University School of Medicine, St Louis, Missouri
authorships[4].institutions[0].id	https://openalex.org/I204465549
authorships[4].institutions[0].ror	https://ror.org/01yc7t268
authorships[4].institutions[0].type	education
authorships[4].institutions[0].lineage	https://openalex.org/I204465549
authorships[4].institutions[0].country_code	US
authorships[4].institutions[0].display_name	Washington University in St. Louis
authorships[4].author_position	middle
authorships[4].raw_author_name	Rajendra S. Apte
authorships[4].is_corresponding	False
authorships[4].raw_affiliation_strings	Washington University School of Medicine, St Louis, Missouri
authorships[5].author.id	https://openalex.org/A5082261567
authorships[5].author.orcid	https://orcid.org/0000-0002-5065-6716
authorships[5].author.display_name	Dennis M. Marcus
authorships[5].countries	US
authorships[5].affiliations[0].institution_ids	https://openalex.org/I4210161809
authorships[5].affiliations[0].raw_affiliation_string	Southeast Retina Center Ophthalmology Department, Augusta, Georgia
authorships[5].institutions[0].id	https://openalex.org/I4210161809
authorships[5].institutions[0].ror	https://ror.org/05q11w119
authorships[5].institutions[0].type	healthcare
authorships[5].institutions[0].lineage	https://openalex.org/I4210161809
authorships[5].institutions[0].country_code	US
authorships[5].institutions[0].display_name	Southeast Retina Center
authorships[5].author_position	middle
authorships[5].raw_author_name	Dennis M. Marcus
authorships[5].is_corresponding	False
authorships[5].raw_affiliation_strings	Southeast Retina Center Ophthalmology Department, Augusta, Georgia
authorships[6].author.id	https://openalex.org/A5057359594
authorships[6].author.orcid	https://orcid.org/0000-0002-7997-7249
authorships[6].author.display_name	Kristīne Baumane
authorships[6].countries	LV
authorships[6].affiliations[0].institution_ids	https://openalex.org/I4210097420
authorships[6].affiliations[0].raw_affiliation_string	Riga East Clinical University Hospital, Riga, Latvia
authorships[6].institutions[0].id	https://openalex.org/I4210097420
authorships[6].institutions[0].ror	https://ror.org/00ss42h10
authorships[6].institutions[0].type	healthcare
authorships[6].institutions[0].lineage	https://openalex.org/I4210097420
authorships[6].institutions[0].country_code	LV
authorships[6].institutions[0].display_name	Riga East University Hospital
authorships[6].author_position	middle
authorships[6].raw_author_name	Kristine Baumane
authorships[6].is_corresponding	False
authorships[6].raw_affiliation_strings	Riga East Clinical University Hospital, Riga, Latvia
authorships[7].author.id	https://openalex.org/A5020224240
authorships[7].author.orcid	https://orcid.org/0000-0001-7169-1839
authorships[7].author.display_name	Somesh Agarwal
authorships[7].countries	IN
authorships[7].affiliations[0].institution_ids	https://openalex.org/I64157871
authorships[7].affiliations[0].raw_affiliation_string	M & J Institute of Ophthalmology–BJ Medical College, Gujarat, India
authorships[7].institutions[0].id	https://openalex.org/I64157871
authorships[7].institutions[0].ror	https://ror.org/0408b4j80
authorships[7].institutions[0].type	healthcare
authorships[7].institutions[0].lineage	https://openalex.org/I64157871
authorships[7].institutions[0].country_code	IN
authorships[7].institutions[0].display_name	B.J. Medical College
authorships[7].author_position	middle
authorships[7].raw_author_name	Somesh Agarwal
authorships[7].is_corresponding	False
authorships[7].raw_affiliation_strings	M & J Institute of Ophthalmology–BJ Medical College, Gujarat, India
authorships[8].author.id	https://openalex.org/A5029122676
authorships[8].author.orcid
authorships[8].author.display_name	Piotr Oleksy
authorships[8].countries	PL
authorships[8].affiliations[0].institution_ids	https://openalex.org/I4210120140
authorships[8].affiliations[0].raw_affiliation_string	Centrum Medyczne UNO-MED, Tarnow, Poland
authorships[8].institutions[0].id	https://openalex.org/I4210120140
authorships[8].institutions[0].ror	https://ror.org/02vspvr81
authorships[8].institutions[0].type	healthcare
authorships[8].institutions[0].lineage	https://openalex.org/I4210120140
authorships[8].institutions[0].country_code	PL
authorships[8].institutions[0].display_name	Centrum Medyczne iMed24
authorships[8].author_position	middle
authorships[8].raw_author_name	Piotr Oleksy
authorships[8].is_corresponding	False
authorships[8].raw_affiliation_strings	Centrum Medyczne UNO-MED, Tarnow, Poland
authorships[9].author.id	https://openalex.org/A5052385927
authorships[9].author.orcid	https://orcid.org/0000-0003-2673-876X
authorships[9].author.display_name	David A. Reichstein
authorships[9].countries	US
authorships[9].affiliations[0].institution_ids	https://openalex.org/I4210158047
authorships[9].affiliations[0].raw_affiliation_string	Tennessee Retina, Nashville
authorships[9].institutions[0].id	https://openalex.org/I4210158047
authorships[9].institutions[0].ror	https://ror.org/055papc77
authorships[9].institutions[0].type	healthcare
authorships[9].institutions[0].lineage	https://openalex.org/I4210158047
authorships[9].institutions[0].country_code	US
authorships[9].institutions[0].display_name	Tennessee Retina
authorships[9].author_position	middle
authorships[9].raw_author_name	David A. Reichstein
authorships[9].is_corresponding	False
authorships[9].raw_affiliation_strings	Tennessee Retina, Nashville
authorships[10].author.id	https://openalex.org/A5104688312
authorships[10].author.orcid
authorships[10].author.display_name	Sunil S. Patel
authorships[10].countries	US
authorships[10].affiliations[0].institution_ids	https://openalex.org/I4210123700
authorships[10].affiliations[0].raw_affiliation_string	Retina Research Institute of Texas, Abilene
authorships[10].institutions[0].id	https://openalex.org/I4210123700
authorships[10].institutions[0].ror	https://ror.org/0260mkc43
authorships[10].institutions[0].type	facility
authorships[10].institutions[0].lineage	https://openalex.org/I4210123700
authorships[10].institutions[0].country_code	US
authorships[10].institutions[0].display_name	Retina Research Institute of Texas
authorships[10].author_position	middle
authorships[10].raw_author_name	Sunil S. Patel
authorships[10].is_corresponding	False
authorships[10].raw_affiliation_strings	Retina Research Institute of Texas, Abilene
authorships[11].author.id	https://openalex.org/A5016649501
authorships[11].author.orcid
authorships[11].author.display_name	Jan Ernest
authorships[11].affiliations[0].raw_affiliation_string	Axon Clinical SRO, Praha 5-Smíchov, Czech Republic
authorships[11].author_position	middle
authorships[11].raw_author_name	Jan Ernest
authorships[11].is_corresponding	False
authorships[11].raw_affiliation_strings	Axon Clinical SRO, Praha 5-Smíchov, Czech Republic
authorships[12].author.id	https://openalex.org/A5074074059
authorships[12].author.orcid
authorships[12].author.display_name	Rózsa Dégı̀
authorships[12].countries	HU
authorships[12].affiliations[0].institution_ids	https://openalex.org/I227486990
authorships[12].affiliations[0].raw_affiliation_string	University of Szeged, Koranyi Favor 10-11, Szeged, Hungary
authorships[12].institutions[0].id	https://openalex.org/I227486990
authorships[12].institutions[0].ror	https://ror.org/01pnej532
authorships[12].institutions[0].type	education
authorships[12].institutions[0].lineage	https://openalex.org/I227486990
authorships[12].institutions[0].country_code	HU
authorships[12].institutions[0].display_name	University of Szeged
authorships[12].author_position	middle
authorships[12].raw_author_name	Rozsa Dégi
authorships[12].is_corresponding	False
authorships[12].raw_affiliation_strings	University of Szeged, Koranyi Favor 10-11, Szeged, Hungary
authorships[13].author.id	https://openalex.org/A5072127135
authorships[13].author.orcid	https://orcid.org/0000-0001-8216-4620
authorships[13].author.display_name	Vishali Gupta
authorships[13].countries	IN
authorships[13].affiliations[0].institution_ids	https://openalex.org/I45294948
authorships[13].affiliations[0].raw_affiliation_string	Postgraduate Institute of Medical Education & Research–Advanced Eye Centre, Punjab, India
authorships[13].institutions[0].id	https://openalex.org/I45294948
authorships[13].institutions[0].ror	https://ror.org/009nfym65
authorships[13].institutions[0].type	education
authorships[13].institutions[0].lineage	https://openalex.org/I45294948
authorships[13].institutions[0].country_code	IN
authorships[13].institutions[0].display_name	Post Graduate Institute of Medical Education and Research
authorships[13].author_position	middle
authorships[13].raw_author_name	Vishali Gupta
authorships[13].is_corresponding	False
authorships[13].raw_affiliation_strings	Postgraduate Institute of Medical Education & Research–Advanced Eye Centre, Punjab, India
authorships[14].author.id	https://openalex.org/A5058663696
authorships[14].author.orcid
authorships[14].author.display_name	Genichiro Kishino
authorships[14].countries	JP
authorships[14].affiliations[0].institution_ids	https://openalex.org/I4210156021
authorships[14].affiliations[0].raw_affiliation_string	Kozawa Eye Hospital and Diabetes Center, Ibaraki, Japan
authorships[14].institutions[0].id	https://openalex.org/I4210156021
authorships[14].institutions[0].ror	https://ror.org/0576bwz31
authorships[14].institutions[0].type	healthcare
authorships[14].institutions[0].lineage	https://openalex.org/I4210156021
authorships[14].institutions[0].country_code	JP
authorships[14].institutions[0].display_name	Aizawa Hospital
authorships[14].author_position	middle
authorships[14].raw_author_name	Genichiro Kishino
authorships[14].is_corresponding	False
authorships[14].raw_affiliation_strings	Kozawa Eye Hospital and Diabetes Center, Ibaraki, Japan
authorships[15].author.id	https://openalex.org/A5024732866
authorships[15].author.orcid	https://orcid.org/0000-0001-7666-6456
authorships[15].author.display_name	Motohiro Kamei
authorships[15].countries	JP
authorships[15].affiliations[0].institution_ids	https://openalex.org/I4210099598
authorships[15].affiliations[0].raw_affiliation_string	Aichi Medical University Hospital, Aichi, Japan
authorships[15].institutions[0].id	https://openalex.org/I4210099598
authorships[15].institutions[0].ror	https://ror.org/00ztar512
authorships[15].institutions[0].type	education
authorships[15].institutions[0].lineage	https://openalex.org/I16528096, https://openalex.org/I4210099598
authorships[15].institutions[0].country_code	JP
authorships[15].institutions[0].display_name	Aichi Medical University Hospital
authorships[15].author_position	middle
authorships[15].raw_author_name	Motohiro Kamei
authorships[15].is_corresponding	False
authorships[15].raw_affiliation_strings	Aichi Medical University Hospital, Aichi, Japan
authorships[16].author.id	https://openalex.org/A5041082309
authorships[16].author.orcid	https://orcid.org/0000-0001-7186-0049
authorships[16].author.display_name	Subramanian Loganathan
authorships[16].countries	IN
authorships[16].affiliations[0].institution_ids	https://openalex.org/I4210143327
authorships[16].affiliations[0].raw_affiliation_string	Clinical Development & Medical Affairs Department, Biocon Biologics Ltd, Bangalore, Karnataka, India
authorships[16].institutions[0].id	https://openalex.org/I4210143327
authorships[16].institutions[0].ror	https://ror.org/047kynf18
authorships[16].institutions[0].type	company
authorships[16].institutions[0].lineage	https://openalex.org/I4210143327
authorships[16].institutions[0].country_code	IN
authorships[16].institutions[0].display_name	Biocon (India)
authorships[16].author_position	middle
authorships[16].raw_author_name	Subramanian Loganathan
authorships[16].is_corresponding	False
authorships[16].raw_affiliation_strings	Clinical Development & Medical Affairs Department, Biocon Biologics Ltd, Bangalore, Karnataka, India
authorships[17].author.id	https://openalex.org/A5110587056
authorships[17].author.orcid
authorships[17].author.display_name	Nauman Chaudhry
authorships[17].countries	HK
authorships[17].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[17].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[17].institutions[0].id	https://openalex.org/I4210099567
authorships[17].institutions[0].ror	https://ror.org/010t34638
authorships[17].institutions[0].type	company
authorships[17].institutions[0].lineage	https://openalex.org/I4210099567
authorships[17].institutions[0].country_code	HK
authorships[17].institutions[0].display_name	Insight (China)
authorships[17].author_position	middle
authorships[17].raw_author_name	Nauman A Chaudhry
authorships[17].is_corresponding	False
authorships[17].raw_affiliation_strings	for the INSIGHT Study Group
authorships[18].author.id	https://openalex.org/A5052385927
authorships[18].author.orcid	https://orcid.org/0000-0003-2673-876X
authorships[18].author.display_name	David A. Reichstein
authorships[18].countries	HK
authorships[18].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[18].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[18].institutions[0].id	https://openalex.org/I4210099567
authorships[18].institutions[0].ror	https://ror.org/010t34638
authorships[18].institutions[0].type	company
authorships[18].institutions[0].lineage	https://openalex.org/I4210099567
authorships[18].institutions[0].country_code	HK
authorships[18].institutions[0].display_name	Insight (China)
authorships[18].author_position	middle
authorships[18].raw_author_name	David A Reichstein
authorships[18].is_corresponding	False
authorships[18].raw_affiliation_strings	for the INSIGHT Study Group
authorships[19].author.id	https://openalex.org/A5082842156
authorships[19].author.orcid
authorships[19].author.display_name	Ali Tabassian
authorships[19].countries	HK
authorships[19].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[19].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[19].institutions[0].id	https://openalex.org/I4210099567
authorships[19].institutions[0].ror	https://ror.org/010t34638
authorships[19].institutions[0].type	company
authorships[19].institutions[0].lineage	https://openalex.org/I4210099567
authorships[19].institutions[0].country_code	HK
authorships[19].institutions[0].display_name	Insight (China)
authorships[19].author_position	middle
authorships[19].raw_author_name	Ali R Tabassian
authorships[19].is_corresponding	False
authorships[19].raw_affiliation_strings	for the INSIGHT Study Group
authorships[20].author.id	https://openalex.org/A5114046426
authorships[20].author.orcid
authorships[20].author.display_name	Howard F. Fine
authorships[20].countries	HK
authorships[20].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[20].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[20].institutions[0].id	https://openalex.org/I4210099567
authorships[20].institutions[0].ror	https://ror.org/010t34638
authorships[20].institutions[0].type	company
authorships[20].institutions[0].lineage	https://openalex.org/I4210099567
authorships[20].institutions[0].country_code	HK
authorships[20].institutions[0].display_name	Insight (China)
authorships[20].author_position	middle
authorships[20].raw_author_name	Howard F Fine
authorships[20].is_corresponding	False
authorships[20].raw_affiliation_strings	for the INSIGHT Study Group
authorships[21].author.id	https://openalex.org/A5009631167
authorships[21].author.orcid
authorships[21].author.display_name	Raymond N. Sjaarda
authorships[21].countries	HK
authorships[21].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[21].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[21].institutions[0].id	https://openalex.org/I4210099567
authorships[21].institutions[0].ror	https://ror.org/010t34638
authorships[21].institutions[0].type	company
authorships[21].institutions[0].lineage	https://openalex.org/I4210099567
authorships[21].institutions[0].country_code	HK
authorships[21].institutions[0].display_name	Insight (China)
authorships[21].author_position	middle
authorships[21].raw_author_name	Raymond N Sjaarda
authorships[21].is_corresponding	False
authorships[21].raw_affiliation_strings	for the INSIGHT Study Group
authorships[22].author.id	https://openalex.org/A5082261567
authorships[22].author.orcid	https://orcid.org/0000-0002-5065-6716
authorships[22].author.display_name	Dennis M. Marcus
authorships[22].countries	HK
authorships[22].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[22].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[22].institutions[0].id	https://openalex.org/I4210099567
authorships[22].institutions[0].ror	https://ror.org/010t34638
authorships[22].institutions[0].type	company
authorships[22].institutions[0].lineage	https://openalex.org/I4210099567
authorships[22].institutions[0].country_code	HK
authorships[22].institutions[0].display_name	Insight (China)
authorships[22].author_position	middle
authorships[22].raw_author_name	Dennis M Marcus
authorships[22].is_corresponding	False
authorships[22].raw_affiliation_strings	for the INSIGHT Study Group
authorships[23].author.id	https://openalex.org/A5020258318
authorships[23].author.orcid	https://orcid.org/0000-0002-1328-6314
authorships[23].author.display_name	Mark Barakat
authorships[23].countries	HK
authorships[23].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[23].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[23].institutions[0].id	https://openalex.org/I4210099567
authorships[23].institutions[0].ror	https://ror.org/010t34638
authorships[23].institutions[0].type	company
authorships[23].institutions[0].lineage	https://openalex.org/I4210099567
authorships[23].institutions[0].country_code	HK
authorships[23].institutions[0].display_name	Insight (China)
authorships[23].author_position	middle
authorships[23].raw_author_name	Mark R Barakat
authorships[23].is_corresponding	False
authorships[23].raw_affiliation_strings	for the INSIGHT Study Group
authorships[24].author.id	https://openalex.org/A5026181496
authorships[24].author.orcid
authorships[24].author.display_name	Pravin U. Dugel
authorships[24].countries	HK
authorships[24].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[24].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[24].institutions[0].id	https://openalex.org/I4210099567
authorships[24].institutions[0].ror	https://ror.org/010t34638
authorships[24].institutions[0].type	company
authorships[24].institutions[0].lineage	https://openalex.org/I4210099567
authorships[24].institutions[0].country_code	HK
authorships[24].institutions[0].display_name	Insight (China)
authorships[24].author_position	middle
authorships[24].raw_author_name	Pravin U Dugel,
authorships[24].is_corresponding	False
authorships[24].raw_affiliation_strings	for the INSIGHT Study Group
authorships[25].author.id	https://openalex.org/A5045129262
authorships[25].author.orcid	https://orcid.org/0000-0003-0654-0668
authorships[25].author.display_name	David Eichenbaum
authorships[25].countries	HK
authorships[25].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[25].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[25].institutions[0].id	https://openalex.org/I4210099567
authorships[25].institutions[0].ror	https://ror.org/010t34638
authorships[25].institutions[0].type	company
authorships[25].institutions[0].lineage	https://openalex.org/I4210099567
authorships[25].institutions[0].country_code	HK
authorships[25].institutions[0].display_name	Insight (China)
authorships[25].author_position	middle
authorships[25].raw_author_name	David A Eichenbaum
authorships[25].is_corresponding	False
authorships[25].raw_affiliation_strings	for the INSIGHT Study Group
authorships[26].author.id	https://openalex.org/A5086270037
authorships[26].author.orcid
authorships[26].author.display_name	Amr Dessouki
authorships[26].countries	HK
authorships[26].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[26].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[26].institutions[0].id	https://openalex.org/I4210099567
authorships[26].institutions[0].ror	https://ror.org/010t34638
authorships[26].institutions[0].type	company
authorships[26].institutions[0].lineage	https://openalex.org/I4210099567
authorships[26].institutions[0].country_code	HK
authorships[26].institutions[0].display_name	Insight (China)
authorships[26].author_position	middle
authorships[26].raw_author_name	Amr L Dessouki
authorships[26].is_corresponding	False
authorships[26].raw_affiliation_strings	for the INSIGHT Study Group
authorships[27].author.id	https://openalex.org/A5075418623
authorships[27].author.orcid	https://orcid.org/0000-0002-1302-4007
authorships[27].author.display_name	Adam Berger
authorships[27].countries	HK
authorships[27].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[27].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[27].institutions[0].id	https://openalex.org/I4210099567
authorships[27].institutions[0].ror	https://ror.org/010t34638
authorships[27].institutions[0].type	company
authorships[27].institutions[0].lineage	https://openalex.org/I4210099567
authorships[27].institutions[0].country_code	HK
authorships[27].institutions[0].display_name	Insight (China)
authorships[27].author_position	middle
authorships[27].raw_author_name	Adam S Berger
authorships[27].is_corresponding	False
authorships[27].raw_affiliation_strings	for the INSIGHT Study Group
authorships[28].author.id	https://openalex.org/A5089459553
authorships[28].author.orcid
authorships[28].author.display_name	BRYAN N. ANGLE
authorships[28].countries	HK
authorships[28].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[28].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[28].institutions[0].id	https://openalex.org/I4210099567
authorships[28].institutions[0].ror	https://ror.org/010t34638
authorships[28].institutions[0].type	company
authorships[28].institutions[0].lineage	https://openalex.org/I4210099567
authorships[28].institutions[0].country_code	HK
authorships[28].institutions[0].display_name	Insight (China)
authorships[28].author_position	middle
authorships[28].raw_author_name	Bryan N Angle
authorships[28].is_corresponding	False
authorships[28].raw_affiliation_strings	for the INSIGHT Study Group
authorships[29].author.id	https://openalex.org/A5023266239
authorships[29].author.orcid
authorships[29].author.display_name	Margaret Chang
authorships[29].countries	HK
authorships[29].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[29].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[29].institutions[0].id	https://openalex.org/I4210099567
authorships[29].institutions[0].ror	https://ror.org/010t34638
authorships[29].institutions[0].type	company
authorships[29].institutions[0].lineage	https://openalex.org/I4210099567
authorships[29].institutions[0].country_code	HK
authorships[29].institutions[0].display_name	Insight (China)
authorships[29].author_position	middle
authorships[29].raw_author_name	Margaret A Chang
authorships[29].is_corresponding	False
authorships[29].raw_affiliation_strings	for the INSIGHT Study Group
authorships[30].author.id	https://openalex.org/A5044390932
authorships[30].author.orcid	https://orcid.org/0000-0002-0511-4942
authorships[30].author.display_name	Sunil Patel
authorships[30].countries	HK
authorships[30].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[30].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[30].institutions[0].id	https://openalex.org/I4210099567
authorships[30].institutions[0].ror	https://ror.org/010t34638
authorships[30].institutions[0].type	company
authorships[30].institutions[0].lineage	https://openalex.org/I4210099567
authorships[30].institutions[0].country_code	HK
authorships[30].institutions[0].display_name	Insight (China)
authorships[30].author_position	middle
authorships[30].raw_author_name	Sunil S Patel
authorships[30].is_corresponding	False
authorships[30].raw_affiliation_strings	for the INSIGHT Study Group
authorships[31].author.id	https://openalex.org/A5102897222
authorships[31].author.orcid	https://orcid.org/0000-0002-2570-5766
authorships[31].author.display_name	David M. Brown
authorships[31].countries	HK
authorships[31].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[31].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[31].institutions[0].id	https://openalex.org/I4210099567
authorships[31].institutions[0].ror	https://ror.org/010t34638
authorships[31].institutions[0].type	company
authorships[31].institutions[0].lineage	https://openalex.org/I4210099567
authorships[31].institutions[0].country_code	HK
authorships[31].institutions[0].display_name	Insight (China)
authorships[31].author_position	middle
authorships[31].raw_author_name	David M Brown
authorships[31].is_corresponding	False
authorships[31].raw_affiliation_strings	for the INSIGHT Study Group
authorships[32].author.id	https://openalex.org/A5111173616
authorships[32].author.orcid
authorships[32].author.display_name	Allen B. Thach
authorships[32].countries	HK
authorships[32].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[32].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[32].institutions[0].id	https://openalex.org/I4210099567
authorships[32].institutions[0].ror	https://ror.org/010t34638
authorships[32].institutions[0].type	company
authorships[32].institutions[0].lineage	https://openalex.org/I4210099567
authorships[32].institutions[0].country_code	HK
authorships[32].institutions[0].display_name	Insight (China)
authorships[32].author_position	middle
authorships[32].raw_author_name	Allen B Thach
authorships[32].is_corresponding	False
authorships[32].raw_affiliation_strings	for the INSIGHT Study Group
authorships[33].author.id	https://openalex.org/A5062651062
authorships[33].author.orcid	https://orcid.org/0000-0003-4048-9923
authorships[33].author.display_name	Carl W. Baker
authorships[33].countries	HK
authorships[33].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[33].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[33].institutions[0].id	https://openalex.org/I4210099567
authorships[33].institutions[0].ror	https://ror.org/010t34638
authorships[33].institutions[0].type	company
authorships[33].institutions[0].lineage	https://openalex.org/I4210099567
authorships[33].institutions[0].country_code	HK
authorships[33].institutions[0].display_name	Insight (China)
authorships[33].author_position	middle
authorships[33].raw_author_name	Carl W Baker
authorships[33].is_corresponding	False
authorships[33].raw_affiliation_strings	for the INSIGHT Study Group
authorships[34].author.id	https://openalex.org/A5114225717
authorships[34].author.orcid
authorships[34].author.display_name	Alan J Gordon
authorships[34].countries	HK
authorships[34].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[34].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[34].institutions[0].id	https://openalex.org/I4210099567
authorships[34].institutions[0].ror	https://ror.org/010t34638
authorships[34].institutions[0].type	company
authorships[34].institutions[0].lineage	https://openalex.org/I4210099567
authorships[34].institutions[0].country_code	HK
authorships[34].institutions[0].display_name	Insight (China)
authorships[34].author_position	middle
authorships[34].raw_author_name	Alan J Gordon
authorships[34].is_corresponding	False
authorships[34].raw_affiliation_strings	for the INSIGHT Study Group
authorships[35].author.id	https://openalex.org/A5051417072
authorships[35].author.orcid	https://orcid.org/0000-0002-0345-0467
authorships[35].author.display_name	Sam E. Mansour
authorships[35].countries	HK
authorships[35].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[35].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[35].institutions[0].id	https://openalex.org/I4210099567
authorships[35].institutions[0].ror	https://ror.org/010t34638
authorships[35].institutions[0].type	company
authorships[35].institutions[0].lineage	https://openalex.org/I4210099567
authorships[35].institutions[0].country_code	HK
authorships[35].institutions[0].display_name	Insight (China)
authorships[35].author_position	middle
authorships[35].raw_author_name	Sam E Mansour
authorships[35].is_corresponding	False
authorships[35].raw_affiliation_strings	for the INSIGHT Study Group
authorships[36].author.id	https://openalex.org/A5046340160
authorships[36].author.orcid
authorships[36].author.display_name	Gregory M Fox
authorships[36].countries	HK
authorships[36].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[36].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[36].institutions[0].id	https://openalex.org/I4210099567
authorships[36].institutions[0].ror	https://ror.org/010t34638
authorships[36].institutions[0].type	company
authorships[36].institutions[0].lineage	https://openalex.org/I4210099567
authorships[36].institutions[0].country_code	HK
authorships[36].institutions[0].display_name	Insight (China)
authorships[36].author_position	middle
authorships[36].raw_author_name	Gregory M Fox
authorships[36].is_corresponding	False
authorships[36].raw_affiliation_strings	for the INSIGHT Study Group
authorships[37].author.id	https://openalex.org/A5034688129
authorships[37].author.orcid
authorships[37].author.display_name	D. Virgil Alfaro
authorships[37].countries	HK
authorships[37].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[37].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[37].institutions[0].id	https://openalex.org/I4210099567
authorships[37].institutions[0].ror	https://ror.org/010t34638
authorships[37].institutions[0].type	company
authorships[37].institutions[0].lineage	https://openalex.org/I4210099567
authorships[37].institutions[0].country_code	HK
authorships[37].institutions[0].display_name	Insight (China)
authorships[37].author_position	middle
authorships[37].raw_author_name	Daniel Virgil Alfaro
authorships[37].is_corresponding	False
authorships[37].raw_affiliation_strings	for the INSIGHT Study Group
authorships[38].author.id	https://openalex.org/A5079034327
authorships[38].author.orcid	https://orcid.org/0000-0002-7260-8491
authorships[38].author.display_name	John B. Davies
authorships[38].countries	HK
authorships[38].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[38].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[38].institutions[0].id	https://openalex.org/I4210099567
authorships[38].institutions[0].ror	https://ror.org/010t34638
authorships[38].institutions[0].type	company
authorships[38].institutions[0].lineage	https://openalex.org/I4210099567
authorships[38].institutions[0].country_code	HK
authorships[38].institutions[0].display_name	Insight (China)
authorships[38].author_position	middle
authorships[38].raw_author_name	John B Davies
authorships[38].is_corresponding	False
authorships[38].raw_affiliation_strings	for the INSIGHT Study Group
authorships[39].author.id	https://openalex.org/A5104117604
authorships[39].author.orcid
authorships[39].author.display_name	Ghassan R Ghorayeb
authorships[39].countries	HK
authorships[39].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[39].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[39].institutions[0].id	https://openalex.org/I4210099567
authorships[39].institutions[0].ror	https://ror.org/010t34638
authorships[39].institutions[0].type	company
authorships[39].institutions[0].lineage	https://openalex.org/I4210099567
authorships[39].institutions[0].country_code	HK
authorships[39].institutions[0].display_name	Insight (China)
authorships[39].author_position	middle
authorships[39].raw_author_name	Ghassan R Ghorayeb
authorships[39].is_corresponding	False
authorships[39].raw_affiliation_strings	for the INSIGHT Study Group
authorships[40].author.id	https://openalex.org/A5069232997
authorships[40].author.orcid
authorships[40].author.display_name	Glenn Stoller
authorships[40].countries	HK
authorships[40].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[40].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[40].institutions[0].id	https://openalex.org/I4210099567
authorships[40].institutions[0].ror	https://ror.org/010t34638
authorships[40].institutions[0].type	company
authorships[40].institutions[0].lineage	https://openalex.org/I4210099567
authorships[40].institutions[0].country_code	HK
authorships[40].institutions[0].display_name	Insight (China)
authorships[40].author_position	middle
authorships[40].raw_author_name	Glenn L Stoller
authorships[40].is_corresponding	False
authorships[40].raw_affiliation_strings	for the INSIGHT Study Group
authorships[41].author.id	https://openalex.org/A5109781027
authorships[41].author.orcid
authorships[41].author.display_name	Thomas Mark Johnson
authorships[41].countries	HK
authorships[41].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[41].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[41].institutions[0].id	https://openalex.org/I4210099567
authorships[41].institutions[0].ror	https://ror.org/010t34638
authorships[41].institutions[0].type	company
authorships[41].institutions[0].lineage	https://openalex.org/I4210099567
authorships[41].institutions[0].country_code	HK
authorships[41].institutions[0].display_name	Insight (China)
authorships[41].author_position	middle
authorships[41].raw_author_name	Thomas Mark Johnson
authorships[41].is_corresponding	False
authorships[41].raw_affiliation_strings	for the INSIGHT Study Group
authorships[42].author.id	https://openalex.org/A5024822935
authorships[42].author.orcid	https://orcid.org/0000-0003-1979-6419
authorships[42].author.display_name	Jan Němčanský
authorships[42].countries	HK
authorships[42].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[42].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[42].institutions[0].id	https://openalex.org/I4210099567
authorships[42].institutions[0].ror	https://ror.org/010t34638
authorships[42].institutions[0].type	company
authorships[42].institutions[0].lineage	https://openalex.org/I4210099567
authorships[42].institutions[0].country_code	HK
authorships[42].institutions[0].display_name	Insight (China)
authorships[42].author_position	middle
authorships[42].raw_author_name	Jan Nemcansky
authorships[42].is_corresponding	False
authorships[42].raw_affiliation_strings	for the INSIGHT Study Group
authorships[43].author.id	https://openalex.org/A5112146113
authorships[43].author.orcid
authorships[43].author.display_name	J Řehák
authorships[43].countries	HK
authorships[43].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[43].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[43].institutions[0].id	https://openalex.org/I4210099567
authorships[43].institutions[0].ror	https://ror.org/010t34638
authorships[43].institutions[0].type	company
authorships[43].institutions[0].lineage	https://openalex.org/I4210099567
authorships[43].institutions[0].country_code	HK
authorships[43].institutions[0].display_name	Insight (China)
authorships[43].author_position	middle
authorships[43].raw_author_name	Jiri Rehak
authorships[43].is_corresponding	False
authorships[43].raw_affiliation_strings	for the INSIGHT Study Group
authorships[44].author.id	https://openalex.org/A5042913513
authorships[44].author.orcid	https://orcid.org/0000-0002-9911-4379
authorships[44].author.display_name	Jan Studnička
authorships[44].countries	HK
authorships[44].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[44].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[44].institutions[0].id	https://openalex.org/I4210099567
authorships[44].institutions[0].ror	https://ror.org/010t34638
authorships[44].institutions[0].type	company
authorships[44].institutions[0].lineage	https://openalex.org/I4210099567
authorships[44].institutions[0].country_code	HK
authorships[44].institutions[0].display_name	Insight (China)
authorships[44].author_position	middle
authorships[44].raw_author_name	Jan Studnicka
authorships[44].is_corresponding	False
authorships[44].raw_affiliation_strings	for the INSIGHT Study Group
authorships[45].author.id	https://openalex.org/A5016649501
authorships[45].author.orcid
authorships[45].author.display_name	Jan Ernest
authorships[45].countries	HK
authorships[45].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[45].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[45].institutions[0].id	https://openalex.org/I4210099567
authorships[45].institutions[0].ror	https://ror.org/010t34638
authorships[45].institutions[0].type	company
authorships[45].institutions[0].lineage	https://openalex.org/I4210099567
authorships[45].institutions[0].country_code	HK
authorships[45].institutions[0].display_name	Insight (China)
authorships[45].author_position	middle
authorships[45].raw_author_name	Jan Ernest
authorships[45].is_corresponding	False
authorships[45].raw_affiliation_strings	for the INSIGHT Study Group
authorships[46].author.id	https://openalex.org/A5059144766
authorships[46].author.orcid
authorships[46].author.display_name	Vladimír Korda
authorships[46].countries	HK
authorships[46].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[46].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[46].institutions[0].id	https://openalex.org/I4210099567
authorships[46].institutions[0].ror	https://ror.org/010t34638
authorships[46].institutions[0].type	company
authorships[46].institutions[0].lineage	https://openalex.org/I4210099567
authorships[46].institutions[0].country_code	HK
authorships[46].institutions[0].display_name	Insight (China)
authorships[46].author_position	middle
authorships[46].raw_author_name	Vladimir Korda
authorships[46].is_corresponding	False
authorships[46].raw_affiliation_strings	for the INSIGHT Study Group
authorships[47].author.id	https://openalex.org/A5059187818
authorships[47].author.orcid	https://orcid.org/0000-0001-6254-436X
authorships[47].author.display_name	Miroslav Veith
authorships[47].countries	HK
authorships[47].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[47].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[47].institutions[0].id	https://openalex.org/I4210099567
authorships[47].institutions[0].ror	https://ror.org/010t34638
authorships[47].institutions[0].type	company
authorships[47].institutions[0].lineage	https://openalex.org/I4210099567
authorships[47].institutions[0].country_code	HK
authorships[47].institutions[0].display_name	Insight (China)
authorships[47].author_position	middle
authorships[47].raw_author_name	Miroslav Veith
authorships[47].is_corresponding	False
authorships[47].raw_affiliation_strings	for the INSIGHT Study Group
authorships[48].author.id	https://openalex.org/A5107159931
authorships[48].author.orcid
authorships[48].author.display_name	Daniel Krzyzanek
authorships[48].countries	HK
authorships[48].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[48].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[48].institutions[0].id	https://openalex.org/I4210099567
authorships[48].institutions[0].ror	https://ror.org/010t34638
authorships[48].institutions[0].type	company
authorships[48].institutions[0].lineage	https://openalex.org/I4210099567
authorships[48].institutions[0].country_code	HK
authorships[48].institutions[0].display_name	Insight (China)
authorships[48].author_position	middle
authorships[48].raw_author_name	Daniel Krzyzanek
authorships[48].is_corresponding	False
authorships[48].raw_affiliation_strings	for the INSIGHT Study Group
authorships[49].author.id	https://openalex.org/A5054963697
authorships[49].author.orcid
authorships[49].author.display_name	B Kalvodová
authorships[49].countries	HK
authorships[49].affiliations[0].institution_ids	https://openalex.org/I4210099567
authorships[49].affiliations[0].raw_affiliation_string	for the INSIGHT Study Group
authorships[49].institutions[0].id	https://openalex.org/I4210099567
authorships[49].institutions[0].ror	https://ror.org/010t34638
authorships[49].institutions[0].type	company
authorships[49].institutions[0].lineage	https://openalex.org/I4210099567
authorships[49].institutions[0].country_code	HK
authorships[49].institutions[0].display_name	Insight (China)
authorships[49].author_position	middle
authorships[49].raw_author_name	Bohdana Kalvodova
authorships[49].is_corresponding	False
authorships[49].raw_affiliation_strings	for the INSIGHT Study Group
has_content.pdf	False
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url
open_access.oa_status	green
open_access.any_repository_has_fulltext	False
created_date	2024-09-13T00:00:00
display_name	Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T10170
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	0.9965999722480774
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2731
primary_topic.subfield.display_name	Ophthalmology
primary_topic.display_name	Retinal Diseases and Treatments
related_works	https://openalex.org/W2883175396, https://openalex.org/W2131412691, https://openalex.org/W2941660592, https://openalex.org/W4388448995, https://openalex.org/W2237198389, https://openalex.org/W2019435952, https://openalex.org/W3134869781, https://openalex.org/W2543869410, https://openalex.org/W3190612623, https://openalex.org/W2605993654
cited_by_count	7
counts_by_year[0].year	2025
counts_by_year[0].cited_by_count	7
locations_count	4
best_oa_location.id	pmh:oai:publicatio.bibl.u-szeged.hu:36897
best_oa_location.is_oa	True
best_oa_location.source.id	https://openalex.org/S4306400436
best_oa_location.source.issn
best_oa_location.source.type	repository
best_oa_location.source.is_oa	False
best_oa_location.source.issn_l
best_oa_location.source.is_core	False
best_oa_location.source.is_in_doaj	False
best_oa_location.source.display_name	SZTE Publicatio Repozitórium (University of Szeged)
best_oa_location.source.host_organization	https://openalex.org/I227486990
best_oa_location.source.host_organization_name	University of Szeged
best_oa_location.source.host_organization_lineage	https://openalex.org/I227486990
best_oa_location.license	other-oa
best_oa_location.pdf_url
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	PeerReviewed
best_oa_location.license_id	https://openalex.org/licenses/other-oa
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url
primary_location.id	doi:10.1001/jamaophthalmol.2024.3458
primary_location.is_oa	False
primary_location.source.id	https://openalex.org/S68724622
primary_location.source.issn	2168-6165, 2168-6173
primary_location.source.type	journal
primary_location.source.is_oa	False
primary_location.source.issn_l	2168-6165
primary_location.source.is_core	True
primary_location.source.is_in_doaj	False
primary_location.source.display_name	JAMA Ophthalmology
primary_location.source.host_organization	https://openalex.org/P4310320259
primary_location.source.host_organization_name	American Medical Association
primary_location.source.host_organization_lineage	https://openalex.org/P4310320259
primary_location.license
primary_location.pdf_url
primary_location.version	publishedVersion
primary_location.raw_type	journal-article
primary_location.license_id
primary_location.is_accepted	True
primary_location.is_published	True
primary_location.raw_source_name	JAMA Ophthalmology
primary_location.landing_page_url	https://doi.org/10.1001/jamaophthalmol.2024.3458
publication_date	2024-09-12
publication_year	2024
referenced_works	https://openalex.org/W4379768629, https://openalex.org/W1786299986, https://openalex.org/W2069506532, https://openalex.org/W1967295501, https://openalex.org/W1481978003, https://openalex.org/W2178156144, https://openalex.org/W2173144648, https://openalex.org/W2146673937, https://openalex.org/W922383587, https://openalex.org/W4318930759
referenced_works_count	10
abstract_inverted_index.1	84
abstract_inverted_index.2	87
abstract_inverted_index.4	135
abstract_inverted_index.5	138
abstract_inverted_index.8	145, 174
abstract_inverted_index.A	210
abstract_inverted_index.a	54
abstract_inverted_index.(5	391
abstract_inverted_index.+3	182
abstract_inverted_index.12	300
abstract_inverted_index.18	78
abstract_inverted_index.26	306
abstract_inverted_index.38	102
abstract_inverted_index.52	198
abstract_inverted_index.73	100
abstract_inverted_index.77	63
abstract_inverted_index.8,	238, 277
abstract_inverted_index.At	236, 275
abstract_inverted_index.To	31
abstract_inverted_index.[1	333
abstract_inverted_index.[2	338
abstract_inverted_index.an	38, 108, 176, 431
abstract_inverted_index.as	430
abstract_inverted_index.at	62, 172
abstract_inverted_index.be	3
abstract_inverted_index.by	143
abstract_inverted_index.in	25, 46, 73, 103, 161, 188, 242, 252, 281, 291, 313, 376, 399, 412
abstract_inverted_index.of	36, 99, 127, 179, 195, 201, 212, 262, 310, 323, 328, 334, 339, 344, 349, 356, 361, 368, 384, 392, 397, 428
abstract_inverted_index.or	14, 85, 131, 386
abstract_inverted_index.to	6, 101, 122, 181, 226, 268, 305, 414, 421, 433
abstract_inverted_index.vs	248, 255, 287, 294, 325, 336, 346, 358, 373, 379, 394, 402
abstract_inverted_index.(10	396
abstract_inverted_index.(7)	285, 289
abstract_inverted_index.216	221
abstract_inverted_index.355	213
abstract_inverted_index.52.	149
abstract_inverted_index.8.4	371
abstract_inverted_index.8.7	374
abstract_inverted_index.90%	302
abstract_inverted_index.AEs	312
abstract_inverted_index.CI,	266, 303
abstract_inverted_index.CST	282
abstract_inverted_index.DME	91
abstract_inverted_index.The	154, 258, 308, 363, 382
abstract_inverted_index.US,	67
abstract_inverted_index.[21	360
abstract_inverted_index.[30	355
abstract_inverted_index.[52	327
abstract_inverted_index.[55	322
abstract_inverted_index.and	34, 50, 70, 80, 92, 152, 205, 231, 316, 351, 406, 419
abstract_inverted_index.but	18
abstract_inverted_index.eye	106
abstract_inverted_index.for	137
abstract_inverted_index.may	2
abstract_inverted_index.met	271
abstract_inverted_index.not	20
abstract_inverted_index.the	66, 74, 104, 158, 253, 272, 292, 314, 377, 400
abstract_inverted_index.use	427
abstract_inverted_index.was	53, 157, 244, 283, 370, 389
abstract_inverted_index.μm	286, 290
abstract_inverted_index.(176	233
abstract_inverted_index.(179	228
abstract_inverted_index.(90%	265
abstract_inverted_index.(SD)	365
abstract_inverted_index.(SE)	165, 240, 279
abstract_inverted_index.0.04	263
abstract_inverted_index.1.1%	337
abstract_inverted_index.1.24	269
abstract_inverted_index.176)	398
abstract_inverted_index.177)	393
abstract_inverted_index.178]	324, 335, 345, 357
abstract_inverted_index.2.8%	390
abstract_inverted_index.5.7%	395
abstract_inverted_index.6.56	249
abstract_inverted_index.6.60	245
abstract_inverted_index.62.2	218
abstract_inverted_index.ADAs	388
abstract_inverted_index.BCVA	169, 243
abstract_inverted_index.DME.	47
abstract_inverted_index.Main	150
abstract_inverted_index.This	52
abstract_inverted_index.[115	348
abstract_inverted_index.[116	343
abstract_inverted_index.[SD]	216
abstract_inverted_index.age,	217
abstract_inverted_index.arms	318
abstract_inverted_index.been	21
abstract_inverted_index.data	117
abstract_inverted_index.from	120, 167
abstract_inverted_index.have	19
abstract_inverted_index.male	222
abstract_inverted_index.mean	164, 239, 260, 278, 298, 364
abstract_inverted_index.over	197
abstract_inverted_index.that	59
abstract_inverted_index.type	83, 86
abstract_inverted_index.week	148, 173, 237, 276
abstract_inverted_index.were	76, 118, 224, 319
abstract_inverted_index.with	23, 41, 82, 89, 175, 416
abstract_inverted_index.μm;	301
abstract_inverted_index.−3	180, 304
abstract_inverted_index.(0.6%	332
abstract_inverted_index.(1.8)	375
abstract_inverted_index.(2.1)	372
abstract_inverted_index.(mean	215
abstract_inverted_index.11.9%	359
abstract_inverted_index.2021.	124
abstract_inverted_index.29.5%	326
abstract_inverted_index.65.3%	347
abstract_inverted_index.BCVA,	193
abstract_inverted_index.Early	109
abstract_inverted_index.Study	113, 116
abstract_inverted_index.These	424
abstract_inverted_index.Trial	436
abstract_inverted_index.[9.2]	219
abstract_inverted_index.arms.	404
abstract_inverted_index.edema	28
abstract_inverted_index.every	134, 144
abstract_inverted_index.least	162
abstract_inverted_index.older	81
abstract_inverted_index.score	98, 171
abstract_inverted_index.study	105
abstract_inverted_index.total	211, 366
abstract_inverted_index.trial	58
abstract_inverted_index.using	107
abstract_inverted_index.vial)	130
abstract_inverted_index.weeks	136, 146
abstract_inverted_index.years	79
abstract_inverted_index.μm).	307
abstract_inverted_index.(0.55)	246, 250
abstract_inverted_index.(16.9%	354
abstract_inverted_index.(30.9%	321
abstract_inverted_index.(65.2%	342
abstract_inverted_index.(AEs),	204
abstract_inverted_index.(BCVA)	96
abstract_inverted_index.(CST),	192
abstract_inverted_index.(DME).	29
abstract_inverted_index.(Eylea	44
abstract_inverted_index.176]),	329, 340, 350
abstract_inverted_index.176]).	362
abstract_inverted_index.India.	71
abstract_inverted_index.Japan,	69
abstract_inverted_index.access	13
abstract_inverted_index.across	65
abstract_inverted_index.acuity	95
abstract_inverted_index.change	166, 187, 241, 280
abstract_inverted_index.chart.	115
abstract_inverted_index.events	203
abstract_inverted_index.groups	296
abstract_inverted_index.letter	97, 170
abstract_inverted_index.margin	178
abstract_inverted_index.number	194, 367
abstract_inverted_index.ocular	320, 331
abstract_inverted_index.regard	413
abstract_inverted_index.safety	35, 418
abstract_inverted_index.visual	94
abstract_inverted_index.weeks,	199
abstract_inverted_index.years;	220
abstract_inverted_index.−112	284
abstract_inverted_index.−124	288
abstract_inverted_index.(0.5-mg	129
abstract_inverted_index.(ADAs).	208
abstract_inverted_index.(ETDRS)	114
abstract_inverted_index.Design,	48
abstract_inverted_index.Europe,	68
abstract_inverted_index.October	121
abstract_inverted_index.Results	209
abstract_inverted_index.adverse	202
abstract_inverted_index.burden,	17
abstract_inverted_index.centers	64
abstract_inverted_index.central	90, 189
abstract_inverted_index.compare	32
abstract_inverted_index.groups.	257, 381
abstract_inverted_index.letters	247, 251, 264
abstract_inverted_index.macular	27
abstract_inverted_index.outcome	156
abstract_inverted_index.primary	155, 273
abstract_inverted_index.reduced	15
abstract_inverted_index.serious	330, 352
abstract_inverted_index.squares	163
abstract_inverted_index.support	426
abstract_inverted_index.through	147
abstract_inverted_index.−1.16	267
abstract_inverted_index.December	123
abstract_inverted_index.Diabetic	111
abstract_inverted_index.Included	72
abstract_inverted_index.Measures	153
abstract_inverted_index.Outcomes	151
abstract_inverted_index.Setting,	49
abstract_inverted_index.[50.4%])	230
abstract_inverted_index.[60.8%])	223
abstract_inverted_index.adjusted	159, 259
abstract_inverted_index.analysis	75
abstract_inverted_index.analyzed	119
abstract_inverted_index.antidrug	206
abstract_inverted_index.baseline	168
abstract_inverted_index.biologic	8
abstract_inverted_index.clinical	57, 410
abstract_inverted_index.diabetes	88
abstract_inverted_index.diabetic	26
abstract_inverted_index.economic	16
abstract_inverted_index.efficacy	33
abstract_inverted_index.expanded	12
abstract_inverted_index.findings	425
abstract_inverted_index.followed	142
abstract_inverted_index.included	60, 186
abstract_inverted_index.letters)	270
abstract_inverted_index.letters.	183
abstract_inverted_index.offering	11
abstract_inverted_index.outcome.	274
abstract_inverted_index.outcomes	185
abstract_inverted_index.subfield	190
abstract_inverted_index.(adjusted	297
abstract_inverted_index.MLY-1701P	429
abstract_inverted_index.MYL-1701P	128, 227, 254, 293, 315, 378, 401, 408
abstract_inverted_index.Objective	30
abstract_inverted_index.Relevance	407
abstract_inverted_index.Secondary	184
abstract_inverted_index.Treatment	110
abstract_inverted_index.[49.6%]).	235
abstract_inverted_index.efficacy,	415
abstract_inverted_index.evaluated	22
abstract_inverted_index.incidence	200, 309, 383
abstract_inverted_index.nonocular	341, 353
abstract_inverted_index.products,	9
abstract_inverted_index.reference	42, 132, 422, 434
abstract_inverted_index.thickness	191
abstract_inverted_index.Importance	0
abstract_inverted_index.MYL-1701P,	37
abstract_inverted_index.antibodies	207
abstract_inverted_index.comparable	417
abstract_inverted_index.difference	160, 261
abstract_inverted_index.injections	196, 369
abstract_inverted_index.lower-cost	4
abstract_inverted_index.originator	7
abstract_inverted_index.randomized	56, 225
abstract_inverted_index.Biosimilars	1
abstract_inverted_index.Conclusions	405
abstract_inverted_index.Identifier:	439
abstract_inverted_index.NCT03610646	440
abstract_inverted_index.Retinopathy	112
abstract_inverted_index.aflibercept	24, 39, 43, 133, 232, 256, 295, 317, 380, 403
abstract_inverted_index.alternative	432
abstract_inverted_index.biosimilar,	40
abstract_inverted_index.consecutive	139
abstract_inverted_index.difference,	299
abstract_inverted_index.equivalence	177, 411
abstract_inverted_index.individuals	77
abstract_inverted_index.injections,	141
abstract_inverted_index.potentially	10
abstract_inverted_index.Formulations	126
abstract_inverted_index.Participants	51
abstract_inverted_index.Registration	437
abstract_inverted_index.[Regeneron])	45
abstract_inverted_index.aflibercept.	423, 435
abstract_inverted_index.alternatives	5
abstract_inverted_index.demonstrated	409
abstract_inverted_index.intravitreal	140
abstract_inverted_index.participants	61, 214, 229, 234
abstract_inverted_index.Interventions	125
abstract_inverted_index.best-corrected	93
abstract_inverted_index.double-masked,	55
abstract_inverted_index.immunogenicity,	420
abstract_inverted_index.treatment-boosted	387
abstract_inverted_index.treatment-induced	385
abstract_inverted_index.ClinicalTrials.gov	438
abstract_inverted_index.treatment-emergent	311
cited_by_percentile_year.max	99
cited_by_percentile_year.min	98
countries_distinct_count	7
institutions_distinct_count	133
sustainable_development_goals[0].id	https://metadata.un.org/sdg/3
sustainable_development_goals[0].score	0.4300000071525574
sustainable_development_goals[0].display_name	Good health and well-being
citation_normalized_percentile.value	0.95840099
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	True